[1] |
International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues[EB/OL].(2017-09-07)[2023-07-30]. https://www.iarc.who.int/news-events/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-2/.
|
[2] |
ARBER D A, ORAZI A, HASSERJIAN R P, et al. International consensus classification of myeloid neoplasms and acute leukemias:integrating morphologic,clinical,and genomic data[J]. Blood, 2022, 140(11):1200-1228.
|
[3] |
KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization classification of haematolymphoidtumours:myeloid and histiocytic/dendritic neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
|
[4] |
LIU W, HASSERJIAN R P, HU Y, et al. Pure erythroid leukemia:a reassessment of the entity using the 2008 World Health Organization classification[J]. Mod Pathol, 2011, 24(3):375-383.
|
[5] |
LI H, HASSERJIAN R P, KROFT S H, et al. Pure erythroid leukemia and erythroblastic sarcoma evolving from chronic myeloid neoplasms[J]. Am J Clin Pathol, 2016, 145(4):538-551.
DOI
PMID
|
[6] |
WANG S A, HASSERJIAN R P. Acute erythroleukemias,acute megakaryoblastic leukemias,and reactive mimics:a guide to a number of perplexing entities[J]. Am J Clin Pathol, 2015, 144(1):44-60.
|
[7] |
SATO S, KOBAYASHI M, SUZAKI K, et al. Challenging diagnosis of pure erythroid leukemia:a case report and literature review[J]. Hematol Rep, 2022, 14(1):38-44.
|
[8] |
WEINBERG O K, ARBER D A. Erythroleukemia:an update[J]. Curr Oncol Rep, 2021, 23(6):69.
|
[9] |
FANG H, WANG S A, YOU M J, et al. Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors[J]. Cytometry B Clin Cytom, 2022, 102(6):440-447.
|
[10] |
REICHARD K K, TEFFERI A, ABDELMAGID M, et al. Pure(acute)erythroid leukemia:morphology,immunophenotype,cytogenetics,mutations,treatment details,and survival data among 41 Mayo clinic cases[J]. Blood Cancer J, 2022, 12(11):147.
|
[11] |
WANG W, WANG S A, MEDEIROS L J, et al. Pure erythroid leukemia[J]. Am J Hematol, 2017, 92(3):292-296.
DOI
PMID
|
[12] |
FANG H, WANG S A, KHOURY J D, et al. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases[J]. Haematologica, 2022, 107(9):2232-2237.
|
[13] |
REINIG E F, GREIPP P T, CHIU A, et al. De novo pure erythroid leukemia:refining the clinicopathologic and cytogenetic characteristics of a rare entity[J]. Mod Pathol, 2018, 31(5):705-717.
|
[14] |
MONTALBAN-BRAVO G, BENTON C B, WANG S A, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia[J]. Blood, 2017, 129(18):2584-2587.
|
[15] |
ACOBS J W, RAMASWAMY R, STATES V, et al. Chronic myeloid leukemia with pure erythroid leukemia blast crisis[J]. Leuk Lymphoma, 2022, 63(1):212-216.
|
[16] |
LIU L, DUDHEKER N, SUMARRIVA LEZAMA L M, et al. Transformation of polycythemia vera to pure erythroid leukemia[J]. Cureus, 2021, 13(7):e16168.
|
[17] |
SADRZADEH H, HASSERJIAN R, FATHI A T. Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia[J]. Am J Hematol, 2013, 88(3):240-241.
DOI
PMID
|
[18] |
XU M, FINN L S, TSUCHIYA K D, et al. Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia[J]. Pediatr Dev Pathol, 2012, 15(1):76-78.
|
[19] |
JI J, LI Y, FAN L, et al. Pure erythroid leukemia subsequent to acute myelomonocytic leukemia:a case report[J]. Medicine(Baltimore), 2021, 100(15):e25528.
|